Amid A Flurry Of EU Positive Opinions Benlysta And Yervoy Shine, While Fampyra Is Reborn
This article was originally published in The Pink Sheet Daily
Executive Summary
The European Medicines Agency has recommended an impressive number of drugs for approval, including Merck & Co's hepatitis C therapy, Victrelis, Theravance's Vibativ and Amgen's Xgeva.
You may also be interested in...
GSK Gears Up To Fight NICE On Benlysta Setback
In preliminary assessment, NICE says it won't recommend GSK's Benlysta for systemic lupus erythematosus as it is too expensive, but a population subgroup analysis may be able to change the ruling.
GSK Gears Up To Fight NICE On Benlysta Setback
In preliminary assessment, NICE says it won't recommend GSK's Benlysta for systemic lupus erythematosus as it is too expensive, but a population subgroup analysis may be able to change the ruling.
Biogen's Fampyra Gains Conditional Approval In Europe
Biogen must prove additional drug benefits in further study to gain full approval.